Impact BioMedical, INC. (IBO) Operating Margin
- Operating margin · 12 months: Value -14591.43%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -14591.43% | Operating income / revenue. Period ending 2026-06-30. $-5.11M ÷ $35.00K × 100 ≈ -14591.43% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -5.11M USD | Operating Income (Loss) |
| Revenue | 35.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 285.00K USD | Research and Development Expense |
| Selling, general and administration | 2.16M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-5.11M | $35.00K | (m) | $285.00K | $2.16M | -14591.43% |
| 2026-03-31 | $-5.56M | $39.00K | (m) | $283.00K | $2.25M | -14258.97% |
| 2025-12-31 | $-4.28M | $32.00K | $424.00K | $340.00K | $873.00K | -13381.25% |
| 2025-09-30 | $-29.34M | (m) | (m) | $122.00K | $1.05M | (m) |
| 2025-06-30 | $-29.52M | (m) | (m) | $152.00K | $921.00K | (m) |
| 2025-03-31 | $-28.99M | (m) | (m) | $198.00K | $818.00K | (m) |
| 2024-12-31 | $-28.75M | (m) | (m) | $278.00K | $718.00K | (m) |
| 2024-09-30 | $-3.66M | (m) | (m) | $478.00K | $557.00K | (m) |
| 2024-06-30 | $-3.61M | (m) | (m) | $752.00K | $526.00K | (m) |
| 2024-03-31 | $-4.00M | (m) | (m) | $1.02M | $423.00K | (m) |
| 2023-12-31 | $-4.03M | (m) | (m) | $1.15M | $315.00K | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-3.40M | $50.00K | (m) | $1.23M | $325.00K | -6808.00% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |